News | May 29, 2023
Aurobindo Pharma Q4 FY23 PAT up at Rs. 506 Cr
US formulations revenue increased by 11.6% YoY to Rs. 3,045 crore and Europe formulation revenue stood at Rs. 1,660 crore
US formulations revenue increased by 11.6% YoY to Rs. 3,045 crore and Europe formulation revenue stood at Rs. 1,660 crore
Product deliveries scheduled in Q3 of 2023
The product is expected to be launched in June 2023
Indian government seeks to promote collaboration with stakeholders and harness potential for achieving growth and development of sector
The company has reported total income of Rs. 3276.35 crores during the period ended March 31, 2023
The company has reported total income of Rs. 880.59 crores during the period ended March 31, 2023
For Q4 ended FY23, company reported net profit of Rs. 12.56 crore as against net profit of Rs. 11.02 crore in the corresponding period last year
Continues to Expand its Presence in South India
The company has reported total income of Rs. 2188.08 crores during the period ended March 31, 2023
Ensures efficient testing of FeNO as it is a simple tool for the diagnosis, screening & monitoring of Asthma patients
Subscribe To Our Newsletter & Stay Updated
